Neuromuscular toxicities of paclitaxel 210 mg m-2 by 3-hour infusion

被引：20

作者：

Kunitoh, H

Saijo, N

Furuse, K

Noda, K

Ogawa, M

机构：

[1] Natl Canc Ctr, Dept Med Oncol, Chuo Ku, Tokyo 104, Japan

[2] Natl Canc Ctr, Res Inst, Div Pharmacol, Tokyo, Japan

[3] Natl Kinki Cent Hosp Chest Dis, Sakai, Osaka, Japan

[4] Kinki Univ, Sch Med, Osakasayama, Japan

[5] Aichi Canc Ctr, Nagoya, Aichi, Japan

来源：

BRITISH JOURNAL OF CANCER | 1998年 / 77卷 / 10期

关键词：

paclitaxel; peripheral neuropathy; myalgia; arthralgia; pharmacokinetics; risk factor;

D O I：

10.1038/bjc.1998.278

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We retrospectively analysed neuromuscular toxicity associated with paclitaxel 210 mg m(-2) given by 3-h infusion in 247 patients, The severity correlated significantly with total cumulative dose, but could not be predicted by the pretreatment clinical variables or by pharmacokinetic parameters, The toxicity tended to occur in early treatment cycles.

引用

页码：1686 / 1688

页数：3

共 11 条

[1] PERIPHERAL NEUROPATHY FROM TAXOL AND CISPLATIN COMBINATION CHEMOTHERAPY - CLINICAL AND ELECTROPHYSIOLOGICAL STUDIES [J].

CHAUDHRY, V ;

ROWINSKY, EK ;

SARTORIUS, SE ;

DONEHOWER, RC ;

CORNBLATH, DR .

ANNALS OF NEUROLOGY, 1994, 35 (03) :304-311

[2] EUROPEAN-CANADIAN RANDOMIZED TRIAL OF PACLITAXEL IN RELAPSED OVARIAN-CANCER - HIGH-DOSE VERSUS LOW-DOSE AND LONG VERSUS SHORT INFUSION [J].

EISENHAUER, EA ;

HUININK, WWT ;

SWENERTON, KD ;

GIANNI, L ;

MYLES, J ;

VANDERBURG, MEL ;

KERR, I ;

VERMORKEN, JB ;

BUSER, K ;

COLOMBO, N ;

BACON, M ;

SANTABARBARA, P ;

ONETTO, N ;

WINOGRAD, B ;

CANETTA, R .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2654-2666

[3] NONLINEAR PHARMACOKINETICS AND METABOLISM OF PACLITAXEL AND ITS PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS IN HUMANS [J].

GIANNI, L ;

KEARNS, CM ;

GIANI, A ;

CAPRI, G ;

VIGANO, L ;

LOCATELLI, A ;

BONADONNA, G ;

EGORIN, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :180-190

[4]

Gianni L, 1995, Ann Oncol, V6, P861

[5]

*JAP SOC CANC THER, 1993, J JPN SOC CANC THER, V28, P101

[6]

Ohtsu T, 1995, CLIN CANCER RES, V1, P599

[7] PACLITAXEL-INDUCED NEUROPATHY [J].

POSTMA, TJ ;

VERMORKEN, JB ;

LIEFTING, AJM ;

PINEDO, HM ;

HEIMANS, JJ .

ANNALS OF ONCOLOGY, 1995, 6 (05) :489-494

[8] PHASE-I TRIAL OF 3-HOUR INFUSION OF PACLITAXEL WITH OR WITHOUT GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH ADVANCED CANCER [J].

SCHILLER, JH ;

STORER, B ;

TUTSCH, K ;

ARZOOMANIAN, R ;

ALBERTI, D ;

FEIERABEND, C ;

SPRIGGS, D .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) :241-248

[9] PHASE-I AND PHARMACOKINETIC STUDY OF PACLITAXEL BY 24-HOUR INTRAVENOUS-INFUSION [J].

TAMURA, T ;

SASAKI, Y ;

EGUCHI, K ;

SHINKAI, T ;

OHE, Y ;

NISHIO, M ;

KUNIKANE, H ;

ARIOKA, H ;

KARATO, A ;

OMATSU, H ;

NAKASHIMA, H ;

SAIJO, N .

JAPANESE JOURNAL OF CANCER RESEARCH, 1994, 85 (10) :1057-1062

[10] Phase I study of paclitaxel by three-hour infusion: Hypotension just after infusion is one of the major dose-limiting toxicities [J].

Tamura, T ;

Sasaki, Y ;

Nishiwaki, Y ;

Saijo, N .

JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (12) :1203-1209

← 1 2 →